Condensed Consolidated Statements of Operations (USD $) In Thousands, except Share data, unless otherwise specified	3 Months Ended		9 Months Ended
	Sep. 30, 2012	Sep. 30, 2011	Sep. 30, 2012	Sep. 30, 2011
Revenue, net:
Core companion animal health	$ 13,530	$ 14,263	$ 45,811	$ 44,727
Other vaccines, pharmaceuticals and products	3,376	3,345	8,541	9,833
Total revenue, net	16,906	17,608	54,352	54,560
Cost of revenue	10,180	10,781	30,655	31,966
Gross profit	6,726	6,827	23,697	22,594
Operating expenses:
Selling and marketing	4,381	3,753	14,020	11,283
Research and development	180	311	717	1,345
General and administrative	2,192	2,355	7,522	7,131
Total operating expenses	6,753	6,419	22,259	19,759
Operating income	(27)	408	1,438	2,835
Interest and other (income) expense, net	(16)	(64)	69	101
Income before income taxes	(11)	472	1,369	2,734
Current tax expense	16	30	98	189
Deferred tax expense (benefit)	5	154	457	884
Total income tax expense (benefit)	21	184	555	1,073
Net income	$ (32)	$ 288	$ 814	$ 1,661
Basic net income (loss) per share	$ (0.01)	$ 0.06	$ 0.15	$ 0.32
Diluted net income (loss) per share	$ (0.01)	$ 0.05	$ 0.15	$ 0.31
Weighted average outstanding shares used to compute basic net income (loss) per share	5,350,000	5,239,000	5,314,000	5,235,000
Weighted average outstanding shares used to compute diluted net income (loss) per share	5,350,000	5,411,000	5,503,000	5,337,000